<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">34991663</PMID><DateCompleted><Year>2022</Year><Month>04</Month><Day>04</Day></DateCompleted><DateRevised><Year>2022</Year><Month>05</Month><Day>31</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1750-1326</ISSN><JournalIssue CitedMedium="Internet"><Volume>17</Volume><Issue>1</Issue><PubDate><Year>2022</Year><Month>Jan</Month><Day>06</Day></PubDate></JournalIssue><Title>Molecular neurodegeneration</Title><ISOAbbreviation>Mol Neurodegener</ISOAbbreviation></Journal><ArticleTitle>Constitutively active SARM1 variants that induce neuropathy are enriched in ALS patients.</ArticleTitle><Pagination><StartPage>1</StartPage><MedlinePgn>1</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">1</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1186/s13024-021-00511-x</ELocationID><Abstract><AbstractText Label="BACKGROUND">In response to injury, neurons activate a program of organized axon self-destruction initiated by the NAD<sup>+</sup> hydrolase, SARM1. In healthy neurons SARM1 is autoinhibited, but single amino acid changes can abolish autoinhibition leading to constitutively active SARM1 enzymes that promote degeneration when expressed in cultured neurons.</AbstractText><AbstractText Label="METHODS">To investigate whether naturally occurring human variants might disrupt SARM1 autoinhibition and potentially contribute to risk for neurodegenerative disease, we assayed the enzymatic activity of all 42 rare SARM1 alleles identified among 8507 amyotrophic lateral sclerosis (ALS) patients and 9671 controls. We then intrathecally injected mice with virus expressing SARM1 constructs to test the capacity of an ALS-associated constitutively active SARM1 variant to promote neurodegeneration in vivo.</AbstractText><AbstractText Label="RESULTS">Twelve out of 42 SARM1 missense variants or small in-frame deletions assayed exhibit constitutive NADase activity, including more than half of those that are unique to the ALS patients or that occur in multiple patients. There is a&#x2009;&gt;&#x2009;5-fold enrichment of constitutively active variants among patients compared to controls. Expression of constitutively active ALS-associated SARM1 alleles in cultured dorsal root ganglion (DRG) neurons is pro-degenerative and cytotoxic. Intrathecal injection of an AAV expressing the common SARM1 reference allele is innocuous to mice, but a construct harboring SARM1<sup>V184G</sup>, the constitutively active variant found most frequently among the ALS patients, causes axon loss, motor dysfunction, and sustained neuroinflammation.</AbstractText><AbstractText Label="CONCLUSIONS">These results implicate rare hypermorphic SARM1 alleles as candidate genetic risk factors for ALS and other neurodegenerative conditions.</AbstractText><CopyrightInformation>&#xa9; 2022. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Bloom</LastName><ForeName>A Joseph</ForeName><Initials>AJ</Initials><Identifier Source="ORCID">0000-0002-6731-5539</Identifier><AffiliationInfo><Affiliation>Needleman Center for Neurometabolism and Axonal Therapeutics and Department of Genetics, Washington University School of Medicine in Saint Louis, St. Louis, MO, USA. ajbloom@wustl.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mao</LastName><ForeName>Xianrong</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Needleman Center for Neurometabolism and Axonal Therapeutics and Department of Genetics, Washington University School of Medicine in Saint Louis, St. Louis, MO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Strickland</LastName><ForeName>Amy</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Needleman Center for Neurometabolism and Axonal Therapeutics and Department of Genetics, Washington University School of Medicine in Saint Louis, St. Louis, MO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sasaki</LastName><ForeName>Yo</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Needleman Center for Neurometabolism and Axonal Therapeutics and Department of Genetics, Washington University School of Medicine in Saint Louis, St. Louis, MO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Milbrandt</LastName><ForeName>Jeffrey</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Needleman Center for Neurometabolism and Axonal Therapeutics and Department of Genetics, Washington University School of Medicine in Saint Louis, St. Louis, MO, USA. jmilbrandt@wustl.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>DiAntonio</LastName><ForeName>Aaron</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Needleman Center for Neurometabolism and Axonal Therapeutics and Department of Developmental Biology, Washington University School of Medicine in Saint Louis, St. Louis, MO, USA. diantonio@wustl.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R37NS065053</GrantID><Acronym>NH</Acronym><Agency>NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1AG013730</GrantID><Acronym>NH</Acronym><Agency>NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R37 NS065053</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS087632</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 AG013730</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01NS087632</GrantID><Acronym>NH</Acronym><Agency>NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01NS119812</GrantID><Acronym>NH</Acronym><Agency>NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS119812</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>01</Month><Day>06</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Mol Neurodegener</MedlineTA><NlmUniqueID>101266600</NlmUniqueID><ISSNLinking>1750-1326</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D051186">Armadillo Domain Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D003598">Cytoskeletal Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C435689">SARM1 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C543961">SARM1 protein, mouse</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051186" MajorTopicYN="Y">Armadillo Domain Proteins</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001369" MajorTopicYN="N">Axons</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003598" MajorTopicYN="Y">Cytoskeletal Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019636" MajorTopicYN="Y">Neurodegenerative Diseases</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">ALS</Keyword><Keyword MajorTopicYN="N">Axon</Keyword><Keyword MajorTopicYN="N">Human genetics</Keyword><Keyword MajorTopicYN="N">NAD</Keyword><Keyword MajorTopicYN="N">Neurodegeneration</Keyword><Keyword MajorTopicYN="N">Neuropathy</Keyword><Keyword MajorTopicYN="N">SARM1</Keyword></KeywordList><CoiStatement>A.D. and J.M. are co-founders, scientific advisory board members and shareholders of Disarm Therapeutics, a wholly owned subsidiary of Eli Lilly. A.J.B. and Y.S. are consultants to Disarm Therapeutics. The authors have no other competing conflicts or financial interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>9</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>12</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>1</Month><Day>7</Day><Hour>5</Hour><Minute>47</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>1</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>4</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34991663</ArticleId><ArticleId IdType="pmc">PMC8739729</ArticleId><ArticleId IdType="doi">10.1186/s13024-021-00511-x</ArticleId><ArticleId IdType="pii">10.1186/s13024-021-00511-x</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Al-Chalabi A. Don&#x2019;t keep it in the family. Nature. 2017;550(7676):S112. doi: 10.1038/550S112a.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/550S112a</ArticleId><ArticleId IdType="pubmed">29045374</ArticleId></ArticleIdList></Reference><Reference><Citation>Gelfman S, Dugger S, de Araujo Martins Moreno C, et al. A new approach for rare variation collapsing on functional protein domains implicates specific genic regions in ALS. Genome Res. 2019. 10.1101/gr.243592.118.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6499321</ArticleId><ArticleId IdType="pubmed">30940688</ArticleId></ArticleIdList></Reference><Reference><Citation>Farhan SMK, Howrigan DP, Abbott LE, et al. Exome sequencing in amyotrophic lateral sclerosis implicates a novel gene, DNAJC7, encoding a heat-shock protein. Nat Neurosci. 2019;22(12):1966&#x2013;1974. doi: 10.1038/s41593-019-0530-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41593-019-0530-0</ArticleId><ArticleId IdType="pmc">PMC6919277</ArticleId><ArticleId IdType="pubmed">31768050</ArticleId></ArticleIdList></Reference><Reference><Citation>Cirulli ET, Lasseigne BN, Petrovski S, et al. Exome sequencing in amyotrophic lateral sclerosis identifies risk genes and pathways. Science. 2015;(80). 10.1126/science.aaa3650.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4437632</ArticleId><ArticleId IdType="pubmed">25700176</ArticleId></ArticleIdList></Reference><Reference><Citation>Lattante S, Doronzio PN, Marangi G, Conte A, Bisogni G, Bernardo D, Russo T, Lamberti D, Patrizi S, Apollo FP, Lunetta C, Scarlino S, Pozzi L, Zollino M, Riva N, Sabatelli M. Coexistence of variants in TBK1 and in other ALS-related genes elucidates an oligogenic model of pathogenesis in sporadic ALS. Neurobiol Aging. 2019;84:239.e9&#x2013;239.e14. doi: 10.1016/j.neurobiolaging.2019.03.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2019.03.010</ArticleId><ArticleId IdType="pubmed">31000212</ArticleId></ArticleIdList></Reference><Reference><Citation>Lotta LA, Mokrosi&#x144;ski J, Mendes de Oliveira E, et al. Human Gain-of-Function MC4R Variants Show Signaling Bias and Protect against Obesity. Cell. 2019. 10.1016/j.cell.2019.03.044.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6476272</ArticleId><ArticleId IdType="pubmed">31002796</ArticleId></ArticleIdList></Reference><Reference><Citation>Figley MD, DiAntonio A. The SARM1 axon degeneration pathway: control of the NAD+ metabolome regulates axon survival in health and disease. Curr Opin Neurobiol. 2020;63:59&#x2013;66. doi: 10.1016/j.conb.2020.02.012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.conb.2020.02.012</ArticleId><ArticleId IdType="pmc">PMC7483800</ArticleId><ArticleId IdType="pubmed">32311648</ArticleId></ArticleIdList></Reference><Reference><Citation>Gilley J, Ribchester RR, Coleman MP. Sarm1 deletion, but not WldS, confers lifelong Rescue in a Mouse Model of severe Axonopathy. Cell Rep. 2017;21(1):10&#x2013;16. doi: 10.1016/j.celrep.2017.09.027.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2017.09.027</ArticleId><ArticleId IdType="pmc">PMC5640801</ArticleId><ArticleId IdType="pubmed">28978465</ArticleId></ArticleIdList></Reference><Reference><Citation>Ko KW, Devault L, Sasaki Y, Milbrandt J, DiAntonio A. Live imaging reveals the cellular events downstream of SARM1 activation. Elife. 2021;10. 10.7554/eLife.71148.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8612704</ArticleId><ArticleId IdType="pubmed">34779400</ArticleId></ArticleIdList></Reference><Reference><Citation>Gerdts J, Summers DW, Sasaki Y, DiAntonio A, Milbrandt J. Sarm1-mediated axon degeneration requires both SAM and TIR interactions. J Neurosci. 2013;33(33):13569&#x2013;13580. doi: 10.1523/JNEUROSCI.1197-13.2013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.1197-13.2013</ArticleId><ArticleId IdType="pmc">PMC3742939</ArticleId><ArticleId IdType="pubmed">23946415</ArticleId></ArticleIdList></Reference><Reference><Citation>Osterloh JM, Yang J, Rooney TM, et al. dSarm/Sarm1 is required for activation of an injury-induced axon death pathway. Science. 2012;(80). 10.1126/science.1223899.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5225956</ArticleId><ArticleId IdType="pubmed">22678360</ArticleId></ArticleIdList></Reference><Reference><Citation>Ozaki E, Gibbons L, Neto NGB, et al. SARM1 deficiency promotes rod and cone photoreceptor cell survival in a model of retinal degeneration. Life Sci Alliance. 2020. 10.26508/lsa.201900618.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7184027</ArticleId><ArticleId IdType="pubmed">32312889</ArticleId></ArticleIdList></Reference><Reference><Citation>Geisler S, Doan RA, Strickland A, Huang X, Milbrandt J, DiAntonio A. Prevention of vincristine-induced peripheral neuropathy by genetic deletion of SARM1 in mice. Brain. 2016;139(12):3092&#x2013;3108. doi: 10.1093/brain/aww251.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/aww251</ArticleId><ArticleId IdType="pmc">PMC5840884</ArticleId><ArticleId IdType="pubmed">27797810</ArticleId></ArticleIdList></Reference><Reference><Citation>Henninger N, Bouley J, Sikoglu EM, An J, Moore CM, King JA, Bowser R, Freeman MR, Brown RH., Jr Attenuated traumatic axonal injury and improved functional outcome after traumatic brain injury in mice lacking Sarm1. Brain. 2016;139(4):1094&#x2013;1105. doi: 10.1093/brain/aww001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/aww001</ArticleId><ArticleId IdType="pmc">PMC5006226</ArticleId><ArticleId IdType="pubmed">26912636</ArticleId></ArticleIdList></Reference><Reference><Citation>Ko KW, Milbrandt J, DiAntonio A. SARM1 acts downstream of neuroinflammatory and necroptotic signaling to induce axon degeneration. J Cell Biol. 2020;219(8). 10.1083/JCB.201912047.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7401797</ArticleId><ArticleId IdType="pubmed">32609299</ArticleId></ArticleIdList></Reference><Reference><Citation>Sasaki Y, Kakita H, Kubota S, Sene A, Lee TJ, Ban N, et al. SARM1 depletion rescues NMNAT1-dependent photoreceptor cell death and retinal degeneration. Elife. 2020;9. 10.7554/eLife.62027.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7591247</ArticleId><ArticleId IdType="pubmed">33107823</ArticleId></ArticleIdList></Reference><Reference><Citation>Turkiew E, Falconer D, Reed N, H&#xf6;ke A. Deletion of Sarm1 gene is neuroprotective in two models of peripheral neuropathy. J Peripher Nerv Syst. 2017;22(3):162&#x2013;171. doi: 10.1111/jns.12219.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jns.12219</ArticleId><ArticleId IdType="pmc">PMC5585053</ArticleId><ArticleId IdType="pubmed">28485482</ArticleId></ArticleIdList></Reference><Reference><Citation>Ziogas NK, Koliatsos VE. Primary traumatic axonopathy in mice subjected to impact acceleration: a reappraisal of pathology and mechanisms with high-resolution anatomical methods. J Neurosci. 2018;38(16):4031&#x2013;4047. doi: 10.1523/JNEUROSCI.2343-17.2018.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.2343-17.2018</ArticleId><ArticleId IdType="pmc">PMC6705930</ArticleId><ArticleId IdType="pubmed">29567804</ArticleId></ArticleIdList></Reference><Reference><Citation>Huppke P, Wegener E, Gilley J, Angeletti C, Kurth I, Drenth JPH, Stadelmann C, Barrantes-Freer A, Br&#xfc;ck W, Thiele H, N&#xfc;rnberg P, G&#xe4;rtner J, Orsomando G, Coleman MP. Homozygous NMNAT2 mutation in sisters with polyneuropathy and erythromelalgia. Exp Neurol. 2019;320:112958. doi: 10.1016/j.expneurol.2019.112958.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.expneurol.2019.112958</ArticleId><ArticleId IdType="pubmed">31132363</ArticleId></ArticleIdList></Reference><Reference><Citation>Gilley J, Mayer PR, Yu G, Coleman MP. Low levels of NMNAT2 compromise axon development and survival. Hum Mol Genet. 2019;28(3):448&#x2013;458. doi: 10.1093/hmg/ddy356.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddy356</ArticleId><ArticleId IdType="pubmed">30304512</ArticleId></ArticleIdList></Reference><Reference><Citation>Figley MD, Gu W, Nanson JD, Shi Y, Sasaki Y, Cunnea K, et al. SARM1 is a metabolic sensor activated by an increased NMN/NAD+ ratio to trigger axon degeneration. Neuron. 2021;109(7):1118&#x2013;1136.e11. 10.1016/j.neuron.2021.02.009.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8174188</ArticleId><ArticleId IdType="pubmed">33657413</ArticleId></ArticleIdList></Reference><Reference><Citation>Sporny M, Guez-Haddad J, Khazma T, Yaron A, Dessau M, Shkolnisky Y, et al. Structural basis for SARM1 inhibition and activation under energetic stress. Elife. 2020;9. 10.7554/eLife.62021.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7688312</ArticleId><ArticleId IdType="pubmed">33185189</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang Y, Liu T, Lee CH, Chang Q, Yang J, Zhang Z. The NAD+-mediated self-inhibition mechanism of pro-neurodegenerative Sarm1. Nature. 2020;588(7839):658&#x2013;663. doi: 10.1038/s41586-020-2862-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-020-2862-z</ArticleId><ArticleId IdType="pubmed">33053563</ArticleId></ArticleIdList></Reference><Reference><Citation>Shen C, Vohra M, Zhang P, Mao X, Figley MD, Zhu J, Sasaki Y, Wu H, DiAntonio A, Milbrandt J. Multiple domain interfaces mediate SARM1 autoinhibition. Proc Natl Acad Sci. 2021;118(4):e2023151118. doi: 10.1073/pnas.2023151118.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.2023151118</ArticleId><ArticleId IdType="pmc">PMC7848697</ArticleId><ArticleId IdType="pubmed">33468661</ArticleId></ArticleIdList></Reference><Reference><Citation>Bratkowski M, Xie T, Thayer DA, Lad S, Mathur P, Yang YS, Danko G, Burdett TC, Danao J, Cantor A, Kozak JA, Brown SP, Bai X, Sambashivan S. Structural and mechanistic regulation of the pro-degenerative NAD hydrolase SARM1. Cell Rep. 2020;32(5):107999. doi: 10.1016/j.celrep.2020.107999.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2020.107999</ArticleId><ArticleId IdType="pubmed">32755591</ArticleId></ArticleIdList></Reference><Reference><Citation>Fischer LR, Culver DG, Tennant P, Davis AA, Wang M, Castellano-Sanchez A, Khan J, Polak MA, Glass JD. Amyotrophic lateral sclerosis is a distal axonopathy: evidence in mice and man. Exp Neurol. 2004;185(2):232&#x2013;240. doi: 10.1016/j.expneurol.2003.10.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.expneurol.2003.10.004</ArticleId><ArticleId IdType="pubmed">14736504</ArticleId></ArticleIdList></Reference><Reference><Citation>Clark JA, Southam KA, Blizzard CA, King AE, Dickson TC. Axonal degeneration, distal collateral branching and neuromuscular junction architecture alterations occur prior to symptom onset in the SOD1G93A mouse model of amyotrophic lateral sclerosis. J Chem Neuroanat. 2016;76(Pt A):35&#x2013;47. doi: 10.1016/j.jchemneu.2016.03.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jchemneu.2016.03.003</ArticleId><ArticleId IdType="pubmed">27038603</ArticleId></ArticleIdList></Reference><Reference><Citation>Gilley J, Jackson O, Pipis M, et al. Enrichment of SARM1 alleles encoding variants with constitutively hyperactive NADase in patients with ALS and other motor nerve disorders. medRxiv. 2021;2021(06):17.21258268. doi: 10.1101/2021.06.17.21258268.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2021.06.17.21258268</ArticleId><ArticleId IdType="pmc">PMC8735862</ArticleId><ArticleId IdType="pubmed">34796871</ArticleId></ArticleIdList></Reference><Reference><Citation>McGill BE, Barve RA, Maloney SE, et al. Abnormal microglia and enhanced inflammation-related gene transcription in mice with conditional deletion of Ctcf in Camk2a-Cre-expressing neurons. J Neurosci. 2018;38(1):200&#x2013;219. doi: 10.1523/JNEUROSCI.0936-17.2017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.0936-17.2017</ArticleId><ArticleId IdType="pmc">PMC5761433</ArticleId><ArticleId IdType="pubmed">29133437</ArticleId></ArticleIdList></Reference><Reference><Citation>Peters OM, Lewis EA, Osterloh JM, Weiss A, Salameh JS, Metterville J, Brown RH, Freeman MR. Loss of Sarm1 does not suppress motor neuron degeneration in the SOD1 G93A mouse model of amyotrophic lateral sclerosis. Hum Mol Genet. 2018;27(21):3761&#x2013;3771. doi: 10.1093/hmg/ddy260.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddy260</ArticleId><ArticleId IdType="pmc">PMC6196650</ArticleId><ArticleId IdType="pubmed">30010873</ArticleId></ArticleIdList></Reference><Reference><Citation>Sasaki Y, Vohra BPS, Lund FE, Milbrandt J. Nicotinamide mononucleotide adenylyl transferase-mediated axonal protection requires enzymatic activity but not increased levels of neuronal nicotinamide adenine dinucleotide. J Neurosci. 2009;29(17):5525&#x2013;5535. doi: 10.1523/JNEUROSCI.5469-08.2009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.5469-08.2009</ArticleId><ArticleId IdType="pmc">PMC3162248</ArticleId><ArticleId IdType="pubmed">19403820</ArticleId></ArticleIdList></Reference><Reference><Citation>Mao X, Moerman AM, Lucas MM, Barger SW. Inhibition of the activity of a neuronal &#x3ba;B-binding factor by glutamate. J Neurochem. 1999;73(5):1851&#x2013;1858. doi: 10.1046/j.1471-4159.1999.01851.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1046/j.1471-4159.1999.01851.x</ArticleId><ArticleId IdType="pubmed">10537043</ArticleId></ArticleIdList></Reference><Reference><Citation>Sasaki Y, Engber TM, Hughes RO, Figley MD, Wu T, Bosanac T, Devraj R, Milbrandt J, Krauss R, DiAntonio A. cADPR is a gene dosage-sensitive biomarker of SARM1 activity in healthy, compromised, and degenerating axons. Exp Neurol. 2020;329:113252. doi: 10.1016/j.expneurol.2020.113252.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.expneurol.2020.113252</ArticleId><ArticleId IdType="pmc">PMC7302925</ArticleId><ArticleId IdType="pubmed">32087251</ArticleId></ArticleIdList></Reference><Reference><Citation>Chan KY, Jang MJ, Yoo BB, Greenbaum A, Ravi N, Wu WL, S&#xe1;nchez-Guardado L, Lois C, Mazmanian SK, Deverman BE, Gradinaru V. Engineered AAVs for efficient noninvasive gene delivery to the central and peripheral nervous systems. Nat Neurosci. 2017;20(8):1172&#x2013;1179. doi: 10.1038/nn.4593.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nn.4593</ArticleId><ArticleId IdType="pmc">PMC5529245</ArticleId><ArticleId IdType="pubmed">28671695</ArticleId></ArticleIdList></Reference><Reference><Citation>Sasaki Y, Hackett AR, Kim S, Strickland A, Milbrandt J. Dysregulation of NAD+ metabolism induces a Schwann cell dedifferentiation program. J Neurosci. 2018;38(29):6546&#x2013;6562. doi: 10.1523/JNEUROSCI.3304-17.2018.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.3304-17.2018</ArticleId><ArticleId IdType="pmc">PMC6052240</ArticleId><ArticleId IdType="pubmed">29921717</ArticleId></ArticleIdList></Reference><Reference><Citation>Hunter DA, Moradzadeh A, Whitlock EL, Brenner MJ, Myckatyn TM, Wei CH, Tung THH, Mackinnon SE. Binary imaging analysis for comprehensive quantitative histomorphometry of peripheral nerve. J Neurosci Methods. 2007;166(1):116&#x2013;124. doi: 10.1016/j.jneumeth.2007.06.018.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jneumeth.2007.06.018</ArticleId><ArticleId IdType="pmc">PMC2587177</ArticleId><ArticleId IdType="pubmed">17675163</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen YH, Sasaki Y, DiAntonio A, Milbrandt J. SARM1 is required in human derived sensory neurons for injury-induced and neurotoxic axon degeneration. Exp Neurol. 2021;339:113636. doi: 10.1016/j.expneurol.2021.113636.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.expneurol.2021.113636</ArticleId><ArticleId IdType="pmc">PMC8171232</ArticleId><ArticleId IdType="pubmed">33548217</ArticleId></ArticleIdList></Reference><Reference><Citation>Karczewski KJ, Francioli LC, Tiao G, et al. Variation across 141,456 human exomes and genomes reveals the spectrum of loss-of-function intolerance across human protein-coding genes. bioRxiv. 2019. 10.1101/531210.</Citation></Reference><Reference><Citation>van der Spek RAA, van Rheenen W, Pulit SL, Kenna KP, van den Berg LH, Veldink JH. The project MinE databrowser: bringing large-scale whole-genome sequencing in ALS to researchers and the public. Amyotroph Lateral Scler Front Degener. 2019;20(5-6):432&#x2013;440. doi: 10.1080/21678421.2019.1606244.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2019.1606244</ArticleId><ArticleId IdType="pmc">PMC7893599</ArticleId><ArticleId IdType="pubmed">31280677</ArticleId></ArticleIdList></Reference><Reference><Citation>Sievers C, Platt N, Perry VH, Coleman MP, Conforti L. Neurites undergoing Wallerian degeneration show an apoptotic-like process with annexin V positive staining and loss of mitochondrial membrane potential. Neurosci Res. 2003;46(2):161&#x2013;169. doi: 10.1016/S0168-0102(03)00039-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0168-0102(03)00039-7</ArticleId><ArticleId IdType="pubmed">12767479</ArticleId></ArticleIdList></Reference><Reference><Citation>Essuman K, Summers DW, Sasaki Y, Mao X, DiAntonio A, Milbrandt J. The SARM1 toll/Interleukin-1 receptor domain possesses intrinsic NAD+ cleavage activity that promotes pathological axonal degeneration. Neuron. 2017;93(6):1334&#x2013;1343.e5. doi: 10.1016/j.neuron.2017.02.022.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2017.02.022</ArticleId><ArticleId IdType="pmc">PMC6284238</ArticleId><ArticleId IdType="pubmed">28334607</ArticleId></ArticleIdList></Reference><Reference><Citation>Geisler S, Doan RA, Cheng GC, Cetinkaya-Fisgin A, Huang SX, H&#xf6;ke A, et al. Vincristine and bortezomib use distinct upstream mechanisms to activate a common SARM1-dependent axon degeneration program. JCI Insight. 2019;4(17). 10.1172/jci.insight.129920.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6777905</ArticleId><ArticleId IdType="pubmed">31484833</ArticleId></ArticleIdList></Reference><Reference><Citation>Li WH, Huang K, Cai Y, Wang QW, Zhu WJ, Hou YN, et al. Permeant fluorescent probes visualize the activation of SARM1 and uncover an anti-neurodegenerative drug candidate. Elife. 2021;10. 10.7554/eLife.67381.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8143800</ArticleId><ArticleId IdType="pubmed">33944777</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao ZY, Xie XJ, Li WH, et al. A Cell-Permeant Mimetic of NMN Activates SARM1 to Produce Cyclic ADP-Ribose and Induce Non-apoptotic Cell Death. iScience. 2019. 10.1016/j.isci.2019.05.001.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6531917</ArticleId><ArticleId IdType="pubmed">31128467</ArticleId></ArticleIdList></Reference><Reference><Citation>Ying W, Cheruku PS, Bazer FW, Safe SH, Zhou B. Investigation of macrophage polarization using bone marrow derived macrophages. J Vis Exp. 2013;(76). 10.3791/50323.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3728835</ArticleId><ArticleId IdType="pubmed">23851980</ArticleId></ArticleIdList></Reference><Reference><Citation>Mueller M, Wacker K, Ringelstein EB, Hickey WF, Imai Y, Kiefer R. Rapid response of identified resident endoneurial macrophages to nerve injury. Am J Pathol. 2001;159(6):2187&#x2013;2197. doi: 10.1016/S0002-9440(10)63070-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0002-9440(10)63070-2</ArticleId><ArticleId IdType="pmc">PMC1850587</ArticleId><ArticleId IdType="pubmed">11733369</ArticleId></ArticleIdList></Reference><Reference><Citation>Fogh I, Ratti A, Gellera C, et al. A genome-wide association meta-analysis identifies a novel locus at 17q11.2 associated with sporadic amyotrophic lateral sclerosis. Hum Mol Genet. 2014. 10.1093/hmg/ddt587.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3959809</ArticleId><ArticleId IdType="pubmed">24256812</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Rheenen W, Shatunov A, Dekker AM, et al. Genome-wide association analyses identify new risk variants and the genetic architecture of amyotrophic lateral sclerosis. Nat Genet. 2016;48(9):1043&#x2013;1048. doi: 10.1038/ng.3622.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ng.3622</ArticleId><ArticleId IdType="pmc">PMC5556360</ArticleId><ArticleId IdType="pubmed">27455348</ArticleId></ArticleIdList></Reference><Reference><Citation>Melamed Z, L&#xf3;pez-Erauskin J, Baughn MW, et al. Premature polyadenylation-mediated loss of stathmin-2 is a hallmark of TDP-43-dependent neurodegeneration. Nat Neurosci. 2019;22(2):180&#x2013;190. doi: 10.1038/s41593-018-0293-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41593-018-0293-z</ArticleId><ArticleId IdType="pmc">PMC6348009</ArticleId><ArticleId IdType="pubmed">30643298</ArticleId></ArticleIdList></Reference><Reference><Citation>Klim JR, Williams LA, Limone F, Guerra San Juan I, Davis-Dusenbery BN, Mordes DA, Burberry A, Steinbaugh MJ, Gamage KK, Kirchner R, Moccia R, Cassel SH, Chen K, Wainger BJ, Woolf CJ, Eggan K. ALS-implicated protein TDP-43 sustains levels of STMN2, a mediator of motor neuron growth and repair. Nat Neurosci. 2019;22(2):167&#x2013;179. doi: 10.1038/s41593-018-0300-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41593-018-0300-4</ArticleId><ArticleId IdType="pmc">PMC7153761</ArticleId><ArticleId IdType="pubmed">30643292</ArticleId></ArticleIdList></Reference><Reference><Citation>Summers DW, Milbrandt J, DiAntonio A. Palmitoylation enables MAPK-dependent proteostasis of axon survival factors. Proc Natl Acad Sci U S A. 2018;115(37):E8746&#x2013;E8754. doi: 10.1073/pnas.1806933115.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1806933115</ArticleId><ArticleId IdType="pmc">PMC6140512</ArticleId><ArticleId IdType="pubmed">30150401</ArticleId></ArticleIdList></Reference><Reference><Citation>Shin JE, Miller BR, Babetto E, Cho Y, Sasaki Y, Qayum S, Russler EV, Cavalli V, Milbrandt J, DiAntonio A. SCG10 is a JNK target in the axonal degeneration pathway. Proc Natl Acad Sci U S A. 2012;109(52):E3696&#x2013;E3705. doi: 10.1073/pnas.1216204109.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1216204109</ArticleId><ArticleId IdType="pmc">PMC3535671</ArticleId><ArticleId IdType="pubmed">23188802</ArticleId></ArticleIdList></Reference><Reference><Citation>White MA, Lin Z, Kim E, et al. Sarm1 deletion suppresses TDP-43-linked motor neuron degeneration and cortical spine loss. Acta Neuropathol Commun. 2019;7(1). 10.1186/s40478-019-0800-9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6819591</ArticleId><ArticleId IdType="pubmed">31661035</ArticleId></ArticleIdList></Reference><Reference><Citation>Farhan SMK, Howrigan DP, Abbott L, et al. Enrichment of rare protein truncating variants in amyotrophic lateral sclerosis patients. bioRxiv. 2018. 10.1101/307835.</Citation></Reference><Reference><Citation>Kenna KP, Van Doormaal PTC, Dekker AM, et al. NEK1 variants confer susceptibility to amyotrophic lateral sclerosis. Nat Genet. 2016;48(9):1037&#x2013;1042. doi: 10.1038/ng.3626.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ng.3626</ArticleId><ArticleId IdType="pmc">PMC5560030</ArticleId><ArticleId IdType="pubmed">27455347</ArticleId></ArticleIdList></Reference><Reference><Citation>Covarrubias AJ, Perrone R, Grozio A, Verdin E. NAD+ metabolism and its roles in cellular processes during ageing. Nat Rev Mol Cell Biol. 2021;22(2):119&#x2013;141. doi: 10.1038/s41580-020-00313-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41580-020-00313-x</ArticleId><ArticleId IdType="pmc">PMC7963035</ArticleId><ArticleId IdType="pubmed">33353981</ArticleId></ArticleIdList></Reference><Reference><Citation>Lautrup S, Sinclair DA, Mattson MP, Fang EF. NAD(+) in Brain Aging and Neurodegenerative Disorders. Cell Metab. 2019;30(4):630&#x2013;655. doi: 10.1016/j.cmet.2019.09.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cmet.2019.09.001</ArticleId><ArticleId IdType="pmc">PMC6787556</ArticleId><ArticleId IdType="pubmed">31577933</ArticleId></ArticleIdList></Reference><Reference><Citation>de la Rubia JE, Drehmer E, Platero JL, et al. Efficacy and tolerability of EH301 for amyotrophic lateral sclerosis: a randomized, double-blind, placebo-controlled human pilot study. Amyotroph Lateral Scler Frontotemporal Degener. 2019;20(1&#x2013;2):115&#x2013;122. doi: 10.1080/21678421.2018.1536152.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2018.1536152</ArticleId><ArticleId IdType="pubmed">30668199</ArticleId></ArticleIdList></Reference><Reference><Citation>Geisler S, Huang SX, Strickland A, Doan RA, Summers DW, Mao X, Park J, DiAntonio A, Milbrandt J. Gene therapy targeting SARM1 blocks pathological axon degeneration in mice. J Exp Med. 2019;216(2):294&#x2013;303. doi: 10.1084/jem.20181040.</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.20181040</ArticleId><ArticleId IdType="pmc">PMC6363435</ArticleId><ArticleId IdType="pubmed">30642945</ArticleId></ArticleIdList></Reference><Reference><Citation>Neale BM, Rivas MA, Voight BF, Altshuler D, Devlin B, Orho-Melander M, Kathiresan S, Purcell SM, Roeder K, Daly MJ. Testing for an unusual distribution of rare variants. PLoS Genet. 2011;7(3):e1001322. doi: 10.1371/journal.pgen.1001322.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pgen.1001322</ArticleId><ArticleId IdType="pmc">PMC3048375</ArticleId><ArticleId IdType="pubmed">21408211</ArticleId></ArticleIdList></Reference><Reference><Citation>Povysil G, Petrovski S, Hostyk J, Aggarwal V, Allen AS, Goldstein DB. Rare-variant collapsing analyses for complex traits: guidelines and applications. Nat Rev Genet. 2019;20(12):747&#x2013;759. doi: 10.1038/s41576-019-0177-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41576-019-0177-4</ArticleId><ArticleId IdType="pubmed">31605095</ArticleId></ArticleIdList></Reference><Reference><Citation>Gibson G. Rare and common variants: twenty arguments. Nat Rev Genet. 2012;13(2):135&#x2013;145. doi: 10.1038/nrg3118.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrg3118</ArticleId><ArticleId IdType="pmc">PMC4408201</ArticleId><ArticleId IdType="pubmed">22251874</ArticleId></ArticleIdList></Reference><Reference><Citation>Ionita-Laza I, Buxbaum JD, Laird NM, Lange C. A new testing strategy to identify rare variants with either risk or protective effect on disease. PLoS Genet. 2011;7(2):e1001289. doi: 10.1371/journal.pgen.1001289.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pgen.1001289</ArticleId><ArticleId IdType="pmc">PMC3033379</ArticleId><ArticleId IdType="pubmed">21304886</ArticleId></ArticleIdList></Reference><Reference><Citation>Li B, Leal SM. Methods for detecting associations with rare variants for common diseases: application to analysis of sequence data. Am J Hum Genet. 2008;83(3):311&#x2013;321. doi: 10.1016/j.ajhg.2008.06.024.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ajhg.2008.06.024</ArticleId><ArticleId IdType="pmc">PMC2842185</ArticleId><ArticleId IdType="pubmed">18691683</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo MHH, Dauber A, Lippincott MFF, Chan YM, Salem RMM, Hirschhorn JNN. Determinants of power in gene-based burden testing for monogenic disorders. Am J Hum Genet. 2016;99(3):527&#x2013;539. doi: 10.1016/j.ajhg.2016.06.031.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ajhg.2016.06.031</ArticleId><ArticleId IdType="pmc">PMC5011058</ArticleId><ArticleId IdType="pubmed">27545677</ArticleId></ArticleIdList></Reference><Reference><Citation>Garc&#xed;a J-C, Bustos R-H. The Genetic Diagnosis of Neurodegenerative Diseases and Therapeutic Perspectives. Brain Sci. 2018;8(12). 10.3390/brainsci8120222.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6316116</ArticleId><ArticleId IdType="pubmed">30551598</ArticleId></ArticleIdList></Reference><Reference><Citation>Hughes RO, Bosanac T, Mao X, Engber TM, DiAntonio A, Milbrandt J, Devraj R, Krauss R. Small molecule SARM1 inhibitors recapitulate the SARM1&#x2212;/&#x2212; phenotype and allow recovery of a metastable Pool of axons fated to degenerate. Cell Rep. 2021;34(1):108588. doi: 10.1016/j.celrep.2020.108588.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2020.108588</ArticleId><ArticleId IdType="pmc">PMC8179325</ArticleId><ArticleId IdType="pubmed">33406435</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>